HOME > BUSINESS
BUSINESS
- AstraZeneca Files Sipavibart for COVID-19 Prevention in Japan
July 29, 2024
- EU Regulator Rejects Leqembi, Eisai to Seek Re-Examination
July 29, 2024
- Chugai’s H1 Profit Marks 2-Digit Growth on Export to Roche Despite Lower Sales
July 26, 2024
- Takeda Will Stage Recovery at Home after 4 Drug Launches in FY2024: Japan Head
July 26, 2024
- Merck, GTRI Tie Up in Development of Parkinson’s Gene Therapy
July 26, 2024
- Intage, Niigata University Tie Up on Megalin Antagonist Development
July 26, 2024
- Global Pharma Market Grows Double Digit in 2023, Humira Stays Atop Drug Ranking: IQVIA
July 26, 2024
- Amazon Launches Online Pharmacy Service in Japan
July 25, 2024
- Novo, Mitsubishi Logistics to Launch Pilot Drug Transport Using Electric Truck
July 25, 2024
- Nichi-Iko to Join Forces with Kyowa in Generic Production, Eyeing Reorganization
July 24, 2024
- Moderna, University of Tokyo Link Arms on mRNA Technology
July 24, 2024
- Kobayashi Pharma Replaces Management after Beni-Koji Scandal
July 24, 2024
- Axcelead-Teijin JV Anticipates Synergies in Common Disease Areas, Pipelines
July 23, 2024
- Astellas, Osaka University Join Hands in Cell Therapy Research
July 23, 2024
- MSD Seeks Japan Nod for RCC Med Belzutifan
July 23, 2024
- Mochida Files Pediatric Dosage of UC Drug Lialda in Japan
July 23, 2024
- Chugai to Offload Hyperammonemia Drug to Maruishi
July 23, 2024
- Terumo to End Sale of HeartSheet after Panel’s Thumbs-Down
July 22, 2024
- Deciphera’s TGCT Drug Accepted for Review in Europe: Ono
July 22, 2024
- FDA Clears IND for Japan JV’s Peptide-Based COVID Therapy
July 19, 2024
ページ
It’s easy to spot motivated and engaged employees. They are more productive, they go the extra mile, and they display a sense of ownership in their work.But how do you replicate this culture throughout your organization? How do you encourage…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…